MorphoSys AG
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
MOR | F
Overview
Corporate Details
- ISIN(s):
- DE000A3H2XW6
- LEI:
- 529900493806K77LRE72
- Country:
- Germany
- Address:
- Semmelweisstr. 7, 82152 Planegg
- Website:
- https://www.morphosys.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
MorphoSys AG is a global biopharmaceutical company focused on developing innovative cancer therapies. Founded in 1992, the company specializes in creating fully human monoclonal antibodies for therapeutic and research applications. It utilizes various proprietary antibody, protein, and peptide technologies to discover and advance both its own and partnered drug candidates, with a particular emphasis on treatments for blood cancers like leukemia. The company's business model has included both drug development and licensing its technology platforms to pharmaceutical partners. In 2024, Novartis completed its acquisition of MorphoSys, integrating the company's oncology pipeline and antibody expertise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-27 16:00 |
Post-Annual General Meeting Information
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual G…
|
English | 11.5 KB | ||
| 2024-08-05 07:30 |
Delisting Announcement
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and N…
|
English | 12.1 KB | ||
| 2024-07-19 16:46 |
Pre-Annual General Meeting Information
MorphoSys AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am…
|
German | 259.7 KB | ||
| 2024-07-19 15:07 |
Pre-Annual General Meeting Information
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.08.2024…
|
German | 259.7 KB | ||
| 2024-07-18 16:00 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 4.6 KB | ||
| 2024-07-12 22:02 |
Delisting Announcement
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
|
English | 13.2 KB | ||
| 2024-07-12 14:34 |
Legal Proceedings Report
Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
|
English | 12.6 KB | ||
| 2024-07-05 16:00 |
Report Publication Announcement
|
English | 3.9 KB | ||
| 2024-07-02 16:00 |
Major Shareholding Notification
|
English | 14.6 KB | ||
| 2024-06-21 16:00 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 14.3 KB | ||
| 2024-06-20 08:25 |
Delisting Announcement
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merge…
|
English | 21.4 KB | ||
| 2024-06-20 08:06 |
M&A Activity
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of …
|
English | 12.3 KB | ||
| 2024-06-10 16:01 |
Major Shareholding Notification
|
English | 13.4 KB | ||
| 2024-06-10 16:00 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 13.4 KB | ||
| 2024-06-06 22:19 |
Board/Management Information
Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of Morp…
|
English | 10.9 KB |
Automate Your Workflow. Get a real-time feed of all MorphoSys AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for MorphoSys AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-20 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 775.25 EUR |
| 2023-06-07 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 52,800.00 EUR |
| 2023-06-06 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 24,280.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 13,800.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 7,479.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 4,186.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 2,698.00 EUR |
| 2022-11-29 | Reissner, Thomas | Supervisory board | Buy | None | 8,100.00 EUR |
| 2022-11-29 | Reissner, Thomas | Supervisory board | Buy | None | 5,000.00 EUR |
| 2022-11-28 | Vermeylen, Krisja | Supervisory board | Buy | None | 14,860.00 EUR |
